Method of using exendin and GLP-1 to affect the central nervous system
US5846937A · kind A · utility
76Cited by
7References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 3, 1997 |
| Grant date | Dec 8, 1998 |
| Priority date | — |
| Expiry date | Mar 3, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0356
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Agonists of the incretin GLP-1 have been found to have a sedative or anxiolytic effect on the mammalian central nervous system. Additionally, exendin has been found to have an independent sedative effect on the mammalian central nervous system. Conversely, antagonists of GLP-1 increase nervous system activity. The invention relates, in one aspect, to the use of GLP-1 agonists and antagonists to affect the arousal state of the mammalian central nervous system. The invention also relates to novel transgenic mammals in which the GLP-1 receptor gene has been disrupted.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.